Skip to Content
MilliporeSigma
  • Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.

Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.

Human vaccines & immunotherapeutics (2017-08-22)
R Garg, L Latimer, V Gerdts, A Potter, S van Drunen Littel-van den Hurk
ABSTRACT

Respiratory syncytial virus (RSV) is the most common cause of respiratory tract infections in both children and elderly people. In this study we evaluated the short- and long-term protective efficacy of a single intranasal (IN) immunization with a RSV vaccine formulation consisting of a codon-optimized fusion (F) protein formulated with poly(I:C), an innate defense regulator peptide and a polyphosphazene (ΔF/TriAdj). This vaccine induced strong systemic and local immune responses, including RSV F-specific IgG1 and IgG2a, SIgA and virus neutralizing antibodies in mice. Furthermore, ΔF/TriAdj promoted production of IFN-γ-secreting T cells and RSV F

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-Acetyl-D-lactosamine, ≥98% (TLC)
Sigma-Aldrich
SIGMAFAST BCIP®/NBT, tablet